Stan Rose (Feb. 2, 1956- ) is a Ph.D. biologist, seasoned biotechnology executive, and serial entrepreneur. Dr. Rose has spent over two decades working with leading scientists and clinicians to create substantial commercial value from inventions based on genome technology.
Dr. Rose is co-founder, Director and CEO of Transplant Genomics, a molecular diagnostic services company commercializing tests to better manage organ transplant patient care and improve outcomes. He is President of Rose Ventures, Inc., a firm that provides consulting and directing to select clients in the life science research products space, and manages a portfolio of public and private equity investments. Dr. Rose is Chairman of Nabsys, a life sciences company pioneering development of semiconductor-based tools for genome analysis. He is a Director of Cellular Dynamics International, (NASDAQ: ICEL), the world's largest producer of fully functional human cells derived from induced pluripotent stem cells (iPS cells). He is a Director of Invenra, an early stage company developing novel technology for peptide drug discovery. He serves as Chief Business Advisor for SERUMdpt Bioscience, an early stage company developing the first device enabling real-time isolation of plasma/serum from drawn blood without centrifuging. He is also a member of the Executive Board of Solving Organ Shortage, a non-profit foundation whose mission is to promote a unifying vision to solve the organ shortage through close scientific collaboration and inspired public policy
Highlights from his 25+ year career in the genomics research products business include serving as CEO of NimbleGen Systems, Inc., a microarray products company, from 2003 through its acquisition by Roche for $272.5 million in 2007; co-founding and growing Genetic MicroSystems, a microarray instrumentation company that was acquired by Affymetrix for $280 million in 2000; and directing the PCR business for Perkin-Elmer and Applied Biosystems during its most dynamic growth phase in the 1990s. Dr. Rose received his B.A. from Cornell University and his Ph.D. from the Massachusetts Institute of Technology.
- Nabsys Expands Leadership Team to Prepare for Commercialization of Novel DNA Positional Sequencing Technology
- Dynamics International Makes Waves in the Stem Cell Industry
- Stanley Rose On Becoming President and CEO of NimbleGen Systems
- NimbleGen to discontinue IPO after Roche's $272.5 million acquisition
- Roche acquires NimbleGen to gain entry into high-growth research microarrray market
- PhD thesis